Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Randomized, Double-blind, Placebo-controlled, Multiple-dose, Crossover Study of the Effect of ZT-01 on Frequency of Nocturnal Hypoglycemia in Type 1 Diabetes Mellitus

Next Previous
Trial Profile

A Phase 2a Randomized, Double-blind, Placebo-controlled, Multiple-dose, Crossover Study of the Effect of ZT-01 on Frequency of Nocturnal Hypoglycemia in Type 1 Diabetes Mellitus

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ZT-01 (Primary)
  • Indications Hypoglycaemia
  • Focus Therapeutic Use
  • Acronyms ZONE
  • Sponsors Zucara Therapeutics

Most Recent Events

  • 01 May 2025 According to a Zucara Therapeutics media release, the company has completed the second and final closing of its US$25 million Series B Financing, which will enable the completion of this study.
  • 12 Nov 2024 According to a Zucara Therapeutics media release, Proceeds from the Financing are expected to fund the remainder of Zucara's ongoing Phase 2a trial of the effect of ZT-01 On Nocturnal hypoglycemia Events in Type 1 diabetes mellitus (ZONE), and the nonclinical activities to support a once-weekly version of ZT-01.
  • 12 Nov 2024 According to a Zucara Therapeutics media release, Sanofi has made a strategic investment in Zucara as part of the Company's US$20 million Series B financing (the "Financing"). As part of the agreement, Sanofi will receive an exclusive right of first negotiation. The Perceptive Xontogeny Venture Fund has also invested as part of the Financing, which has the potential to increase to up to US$25 million with participation from other investors.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top